Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Fosun Intl. Will Use Healthcare Assets to Create Liquidity

publication date: Sep 1, 2016
Fosun International, China's largest conglomerate and the parent of Fosun Pharma, plans to announce a liquidity event for its healthcare assets before the end of the year. It will be an IPO or an infusion of private equity, said Fosun Chairman Guangchang Guo. Hospitals require large amounts of capital investment, and Fosun, an active M&A player, always wants more capital. In August, Fosun Pharma announced it will pay $1.3 billion for an 86% interest in India's Gland Pharma, a maker of injectible drugs. More details....

Stock Symbols: (HK: 0656) (SHA: 600196; HK: 2196)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
San Francisco, USA
January 6, 2019
Use 'ChinaBio200' to get a USD200 Discount!
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China